Tisch Cancer Institute at Mount Sinai

 

ASH 2021 Conference Coverage on VuMedi
Avatar

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
608 views
December 15, 2021
0 Comments
Login to view comments. Click here to Login
Videos
06:30
Tisch Cancer Institute at Mount Sinai

ASTRO 2023 Insights: "Treatment Landscape for mCRPC - Lu-177-PS…

Feat. W. Oh
10:51
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: Myeloproliferative Neoplasms

Feat. J. Mascarenhas
17:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

Feat. J. Mascarenhas
01:07
WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Cancer and Atopy: Parallel Drivers? I…

Feat. T. Marron
11:14
WCLC 2022 Conference Coverage

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Syner…

Feat. T. Marron
09:41
i3 Health

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofi…

Feat. J. Mascarenhas
05:07
Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

Feat. A. Villanueva
11:42
Icahn School of Medicine at Mount Sinai

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

Feat. M. Kremyanskaya
04:20
Oncology Data Advisor

The Roles of Etiology and Biopsy in Hepatocellular Carcinoma

Feat. A. Villanueva
20:43
Tisch Cancer Institute at Mount Sinai

PD-L1 Expression: Practical Implications in Advanced Stage NSCLC

Feat. F. Hirsch
07:13
ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

Feat. J. Mascarenhas
06:20
ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

Feat. J. Mascarenhas
05:04
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

Feat. A. Villanueva
15:25
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

Feat. M. Kremyanskaya
07:56
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

Feat. J. Mascarenhas
05:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

Feat. J. Mascarenhas
21:07
2021 International Congress on Myeloproliferative Neoplasms

Persistent Leukocytosis and PV Progression: Prognostic and Therapeut…

Feat. J. Mascarenhas
01:47
2021 ASCO Virtual Direct™ Highlights

2021 ASCO Summary on COVID-19 & Cancer

Feat. D. Doroshow
08:32
Tisch Cancer Institute at Mount Sinai

2020 NSCLC Update: Does PD-L1 Predict Pembrolizumab Response in Pati…

Feat. D. Doroshow
06:49
Tisch Cancer Institute at Mount Sinai

Can Pacritinib Be Used to Treat Cytokine Storm in Patients With COVI…

Feat. J. Mascarenhas
28:34
Tisch Cancer Institute at Mount Sinai

Managing Hepatocellular Carcinoma: Early Detection and Diagnosis, St…

Feat. A. Villanueva
07:57
Tisch Cancer Institute at Mount Sinai

Epidemiology of Hepatocellular Carcinoma: Disease Burden and Trends

Feat. A. Villanueva
11:35
Tisch Cancer Institute at Mount Sinai

Clinical Challenges in Management of Hepatocellular Carcinoma: Liqui…

Feat. A. Villanueva
24:22
Tisch Cancer Institute at Mount Sinai

Update on Clinical Trials in Myeloproliferative Neoplasms

Feat. J. Mascarenhas